My work focuses on estimating the benefit-risk balance and the level of evidence of the treatment effect of antithrombotics and immunosuppressants. This modeling is particularly based on conducting meta-analyses (baseline risk, risk stratification and interaction of treatment effect, effect on human subpopulations, and personalized medicine).

This activity has expanded to questions of meta-research, concerning the distortion of treatment effect measurement due to methodological biases and cognitive biases in treatment evaluation. This activity echoes my work within the transparency commission of the HAS.

I have been responsible for the Modeling and Therapeutic Effect Modeling Team since January 2021.

Publications

Display of 1 to 30 publications on 105 in total